Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2Ovarian Neoplasms 1Leiomyoma 1Glioma 1Fibroadenoma 1Carcinoma, Intraductal, Noninfiltrating 1Breast Diseases 1Brain Neoplasms 1

Interventions

Letrozole 5pyrotinib 4Trastuzumab 4Anastrozole 4palbociclib 3exemestane 2abemaciclib 2Sodium Chloride 2Exercise 2Epirubicin 2Drug Evaluation 2Docetaxel 2Cyclophosphamide 2Botulinum Toxins, Type A 2Blood Specimen Collection 2Aromatase Inhibitors 2sacubitril and valsartan sodium hydrate drug combination 1ribociclib 1pertuzumab 1gadoterate meglumine 1Vinorelbine 1Tomography, X-Ray Computed 1Tamoxifen 1Surveys and Questionnaires 1Surgimend 1Surgical Procedures, Operative 1Paclitaxel 1Mammaplasty 1Liquid Biopsy 1Leflunomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Diseases × gadoterate meglumine × Clear all
NCT04341129 2023-12-05

Abbreviated MRI Protocol: Initial Experience With Dotarem® (Gadoterate Meglumine)

University of Chicago

Phase EARLY_PHASE1 Completed
50 enrolled
Breast

Breast Diseases, Breast Neoplasms, Carcinoma, Intraductal, Noninfiltrating, Fibroadenoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡